Doravirine (MK-1439) is a non-nucleoside reverse transcriptase inhibitor developed by Merck & Co. for use in the treatment of HIV/AIDS. In August 2018, the FDA approved doravine under the product name Pifeltro, and in a combination tablet, doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo).

Property Value
dbo:abstract
  • Doravirine (MK-1439) is a non-nucleoside reverse transcriptase inhibitor developed by Merck & Co. for use in the treatment of HIV/AIDS. In August 2018, the FDA approved doravine under the product name Pifeltro, and in a combination tablet, doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo). (en)
dbo:thumbnail
dbo:wikiPageEditLink
dbo:wikiPageExtracted
  • 2019-09-19 01:02:01Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 38749432 (xsd:integer)
dbo:wikiPageLength
  • 3121 (xsd:integer)
dbo:wikiPageModified
  • 2019-09-19 01:00:40Z (xsd:date)
dbo:wikiPageOutDegree
  • 10 (xsd:integer)
dbo:wikiPageRevisionID
  • 916457731 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Doravirine (MK-1439) is a non-nucleoside reverse transcriptase inhibitor developed by Merck & Co. for use in the treatment of HIV/AIDS. In August 2018, the FDA approved doravine under the product name Pifeltro, and in a combination tablet, doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo). (en)
rdfs:label
  • Doravirine (en)
owl:differentFrom
owl:sameAs
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is owl:differentFrom of
is foaf:primaryTopic of